Celcuity to Present at the B. Riley Oncology Investor Conference

Rhea-AI Summary

Celcuity Inc. (Nasdaq: CELC), a biotechnology firm focused on developing companion diagnostics for cancer, announced that CEO Brian Sullivan will present at the B. Riley Oncology Investor Conference on January 21, 2021, at 1:00 pm ET. Attendees can register for the live webcast and participate in online one-on-one meetings with Mr. Sullivan. Following the event, a replay of the presentation will be available on Celcuity's website. The company’s CELsignia platform aims to improve cancer diagnostics and expand treatment options for patients.

Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology company utilizing its 3^rd generation companion diagnostics to identify new targeted therapeutic options for cancer patients, announced today that Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcuity, will present at the B. Riley Oncology Investor Conference to be held January 20-21, 2021.

Mr. Sullivan will present an overview of Celcuity on January 21, 2021 at 1:00 pm ET and participate in online one-on-one meetings with investors who are registered to attend the conference. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup. After completion of the event, a replay of the presentation will be publicly available on the Celcuity website at https://celcuity.com/home/investors/events-webcasts.

About Celcuity

Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity’s 3^rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient’s cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN. Further information about Celcuity can be found at www.celcuity.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005999/en/

FAQ

What is the date and time of Brian Sullivan's presentation at the B. Riley Oncology Investor Conference for Celcuity (CELC)?

Brian Sullivan's presentation at the B. Riley Oncology Investor Conference is scheduled for January 21, 2021, at 1:00 pm ET.

How can I view Brian Sullivan's presentation for Celcuity (CELC)?

You can register to view Brian Sullivan's presentation live at the B. Riley Oncology Investor Conference via the registration link provided in the press release.

Will there be a replay of Brian Sullivan's presentation for Celcuity (CELC)?

Yes, a replay of Brian Sullivan's presentation will be available on Celcuity's website after the conference.

What is Celcuity's focus in the biotechnology field?

Celcuity focuses on developing companion diagnostics to identify targeted therapeutic options for cancer patients.

Where is Celcuity Inc. (CELC) headquartered?

Celcuity Inc. is headquartered in Minneapolis, MN.